Biodexa Pharmaceticals (BDRX) - Total Liabilities
Based on the latest financial reports, Biodexa Pharmaceticals (BDRX) has total liabilities worth $6.76 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biodexa Pharmaceticals - Total Liabilities Trend (2012–2025)
This chart illustrates how Biodexa Pharmaceticals's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Biodexa Pharmaceticals to evaluate short-term liquidity relative to the company's equity base.
Biodexa Pharmaceticals Competitors by Total Liabilities
The table below lists competitors of Biodexa Pharmaceticals ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Savannah Resources Plc
LSE:SAV
|
UK | GBX6.06 Million |
|
KEY Petroleum Ltd
AU:KEY
|
Australia | AU$400.18K |
|
Totalindo Eka Persada Tbk PT
JK:TOPS
|
Indonesia | Rp1.21 Trillion |
|
Kovo Healthtech Corp
V:KOVO
|
Canada | CA$26.79 Million |
|
Winsome Yarns Limited
NSE:WINSOME
|
India | Rs6.43 Billion |
|
Urban-Gro Inc
NASDAQ:UGRO
|
USA | $42.08 Million |
|
DigiAsia Corp
NASDAQ:FAAS
|
USA | $61.18 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Biodexa Pharmaceticals's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Biodexa Pharmaceticals market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biodexa Pharmaceticals's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biodexa Pharmaceticals (2012–2025)
The table below shows the annual total liabilities of Biodexa Pharmaceticals from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $6.76 Million | +4.71% |
| 2024-12-31 | $6.46 Million | +10.13% |
| 2023-12-31 | $5.86 Million | +148.16% |
| 2022-12-31 | $2.36 Million | -3.96% |
| 2021-12-31 | $2.46 Million | -20.60% |
| 2020-12-31 | $3.10 Million | -72.66% |
| 2019-12-31 | $11.34 Million | +222.07% |
| 2018-12-31 | $3.52 Million | -75.80% |
| 2017-12-31 | $14.55 Million | +32.68% |
| 2016-12-31 | $10.96 Million | -36.08% |
| 2015-12-31 | $17.15 Million | +267.01% |
| 2014-12-31 | $4.67 Million | +5.89% |
| 2013-12-31 | $4.41 Million | -62.86% |
| 2012-12-31 | $11.89 Million | -- |
About Biodexa Pharmaceticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment … Read more